RU2017100658A - ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ПРОТИВ Helicobacter - Google Patents
ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ПРОТИВ Helicobacter Download PDFInfo
- Publication number
- RU2017100658A RU2017100658A RU2017100658A RU2017100658A RU2017100658A RU 2017100658 A RU2017100658 A RU 2017100658A RU 2017100658 A RU2017100658 A RU 2017100658A RU 2017100658 A RU2017100658 A RU 2017100658A RU 2017100658 A RU2017100658 A RU 2017100658A
- Authority
- RU
- Russia
- Prior art keywords
- fragment
- amino acids
- immunogenic composition
- htra polypeptide
- htra
- Prior art date
Links
- 241000589989 Helicobacter Species 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 21
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 21
- 238000000034 method Methods 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 230000002163 immunogen Effects 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 206010061218 Inflammation Diseases 0.000 claims 11
- 230000004054 inflammatory process Effects 0.000 claims 11
- 230000001580 bacterial effect Effects 0.000 claims 9
- 241000894006 Bacteria Species 0.000 claims 6
- 241000590002 Helicobacter pylori Species 0.000 claims 6
- 229940037467 helicobacter pylori Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000007882 Gastritis Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims 2
- 206010019375 Helicobacter infections Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010013864 duodenitis Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014902493A AU2014902493A0 (en) | 2014-06-30 | Helicobacter therapeutic | |
| AU2014902493 | 2014-06-30 | ||
| PCT/AU2015/000380 WO2016000022A1 (en) | 2014-06-30 | 2015-06-30 | Helicobacter therapeutic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017100658A true RU2017100658A (ru) | 2018-07-30 |
| RU2017100658A3 RU2017100658A3 (OSRAM) | 2019-02-19 |
Family
ID=55018143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017100658A RU2017100658A (ru) | 2014-06-30 | 2015-06-30 | ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ПРОТИВ Helicobacter |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170165347A1 (OSRAM) |
| EP (1) | EP3160492A4 (OSRAM) |
| JP (1) | JP6634444B2 (OSRAM) |
| KR (1) | KR102481455B1 (OSRAM) |
| CN (2) | CN106573038A (OSRAM) |
| AU (1) | AU2015283805B2 (OSRAM) |
| BR (1) | BR112016030728A2 (OSRAM) |
| RU (1) | RU2017100658A (OSRAM) |
| WO (1) | WO2016000022A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101885460B1 (ko) | 2017-02-07 | 2018-08-03 | 두산중공업 주식회사 | 가스터빈용 프리 스월러 장치 |
| CN108531468B (zh) * | 2018-02-24 | 2020-07-17 | 广东工业大学 | 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用 |
| KR102500799B1 (ko) | 2018-03-09 | 2023-02-20 | 삼성디스플레이 주식회사 | 트랜지스터 기판 및 이를 구비하는 표시 장치 |
| RU2746590C1 (ru) * | 2020-10-12 | 2021-04-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" | Способ эрадикации бактерий Helicobacter pylori при экспериментальном хеликобактериозе у конвенциональных белых мышей и средство для его осуществления |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| AU3210997A (en) | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| EP0977864A2 (en) * | 1997-04-25 | 2000-02-09 | Genelabs Technologies, Inc. | Antigenic composition and method of detection for helicobacter pylori |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| GB9808720D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| US6585975B1 (en) * | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
| AUPP684998A0 (en) * | 1998-10-30 | 1998-11-26 | Murdoch Institute for Research into Birth Defects Limited, The | A method of recombination and agents useful for same |
| US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| US20030180330A1 (en) * | 2000-04-27 | 2003-09-25 | Meyer Thomas F | Method for identifying helicobacter antigens |
| US7015033B1 (en) * | 2000-05-25 | 2006-03-21 | Aventis Pasteur Limited | Co-expression of recombination proteins |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| FR2815544B1 (fr) | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | Seringue sans aiguille securisee a architecture compacte |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| JP2007524366A (ja) * | 2003-04-22 | 2007-08-30 | インターツェル・アクチェンゲゼルシャフト | ピロリ菌抗原 |
| US7868139B2 (en) * | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| BRPI0621476A2 (pt) * | 2006-03-15 | 2011-12-13 | Csir | método assistido por computador de gerar um composto que iniba a atividade de glutamina sintetase, método de gerar um composto de teste, método de triagem de um composto inibidor de protease, método in vitro para inibir crescimento de uma bactéria e uso de um inibidor de serina protease |
| US20110250221A1 (en) * | 2007-08-24 | 2011-10-13 | University Of Wollongong | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof |
| WO2010068413A1 (en) * | 2008-11-25 | 2010-06-17 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
-
2015
- 2015-06-30 US US15/321,933 patent/US20170165347A1/en not_active Abandoned
- 2015-06-30 WO PCT/AU2015/000380 patent/WO2016000022A1/en not_active Ceased
- 2015-06-30 AU AU2015283805A patent/AU2015283805B2/en active Active
- 2015-06-30 RU RU2017100658A patent/RU2017100658A/ru not_active Application Discontinuation
- 2015-06-30 CN CN201580035276.6A patent/CN106573038A/zh active Pending
- 2015-06-30 JP JP2017519730A patent/JP6634444B2/ja active Active
- 2015-06-30 BR BR112016030728A patent/BR112016030728A2/pt not_active Application Discontinuation
- 2015-06-30 KR KR1020177002217A patent/KR102481455B1/ko active Active
- 2015-06-30 EP EP15814180.4A patent/EP3160492A4/en not_active Ceased
- 2015-06-30 CN CN202110962088.5A patent/CN113694191A/zh active Pending
-
2019
- 2019-09-18 US US16/574,625 patent/US20200108135A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/459,715 patent/US11819546B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170165347A1 (en) | 2017-06-15 |
| US20220193216A1 (en) | 2022-06-23 |
| KR20170016989A (ko) | 2017-02-14 |
| EP3160492A4 (en) | 2018-01-03 |
| AU2015283805A1 (en) | 2017-01-05 |
| JP2017521490A (ja) | 2017-08-03 |
| JP6634444B2 (ja) | 2020-01-22 |
| EP3160492A1 (en) | 2017-05-03 |
| RU2017100658A3 (OSRAM) | 2019-02-19 |
| CN113694191A (zh) | 2021-11-26 |
| WO2016000022A1 (en) | 2016-01-07 |
| KR102481455B1 (ko) | 2022-12-26 |
| BR112016030728A2 (pt) | 2018-02-20 |
| US20200108135A1 (en) | 2020-04-09 |
| CN106573038A (zh) | 2017-04-19 |
| AU2015283805B2 (en) | 2021-02-25 |
| US11819546B2 (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI659968B (zh) | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 | |
| JP2011250797A5 (OSRAM) | ||
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| JP2015526440A5 (OSRAM) | ||
| ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
| JP2013534532A5 (OSRAM) | ||
| RU2009102815A (ru) | Полипептиды из neisseria meningitidis | |
| JP2017518958A (ja) | 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用 | |
| RU2017127772A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| MXPA05008156A (es) | Inmunizacion activa para generar anticuerpos para beta-a soluble. | |
| RU2017100658A (ru) | ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ПРОТИВ Helicobacter | |
| JP2016539946A5 (OSRAM) | ||
| RU2017104642A (ru) | Новое антитело против tie-2 человека | |
| JP2016503413A5 (OSRAM) | ||
| JP2018505882A5 (OSRAM) | ||
| JP2016508973A5 (OSRAM) | ||
| RU2014109093A (ru) | Антитела против нейрегулина и их применение | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| JP2017505305A5 (OSRAM) | ||
| JP2018529661A5 (OSRAM) | ||
| EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
| RU2016128223A (ru) | Лечение вируса гриппа а h7n9 | |
| JP2017521490A5 (OSRAM) | ||
| BR112021000025A2 (pt) | Composições e métodos para tratamento de doenças inflamatórias intestinais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200806 |